237 related articles for article (PubMed ID: 32631603)
1. Cancer and Scleroderma.
Weeding E; Casciola-Rosen L; Shah AA
Rheum Dis Clin North Am; 2020 Aug; 46(3):551-564. PubMed ID: 32631603
[TBL] [Abstract][Full Text] [Related]
2. Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications.
Shah AA; Rosen A
Curr Opin Rheumatol; 2011 Nov; 23(6):530-5. PubMed ID: 21825998
[TBL] [Abstract][Full Text] [Related]
3. Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.
Shah AA; Casciola-Rosen L
Curr Opin Rheumatol; 2015 Nov; 27(6):563-70. PubMed ID: 26352736
[TBL] [Abstract][Full Text] [Related]
4. Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients.
Fragoulis GE; Daoussis D; Pagkopoulou E; Garyfallos A; Kitas GD; Dimitroulas T
Expert Rev Clin Immunol; 2020 Dec; 16(12):1105-1113. PubMed ID: 33150792
[No Abstract] [Full Text] [Related]
5. Mechanistic and clinical insights at the scleroderma-cancer interface.
Shah AA; Casciola-Rosen L
J Scleroderma Relat Disord; 2017; 2(3):153-159. PubMed ID: 29264402
[TBL] [Abstract][Full Text] [Related]
6. Intriguing Relationships Between Cancer and Systemic Sclerosis: Role of the Immune System and Other Contributors.
Maria ATJ; Partouche L; Goulabchand R; Rivière S; Rozier P; Bourgier C; Le Quellec A; Morel J; Noël D; Guilpain P
Front Immunol; 2018; 9():3112. PubMed ID: 30687318
[TBL] [Abstract][Full Text] [Related]
7. Cancer and scleroderma: recent insights.
Morrisroe K; Nikpour M
Curr Opin Rheumatol; 2020 Nov; 32(6):479-487. PubMed ID: 33002949
[TBL] [Abstract][Full Text] [Related]
8. Examination of autoantibody status and clinical features associated with cancer risk and cancer-associated scleroderma.
Shah AA; Hummers LK; Casciola-Rosen L; Visvanathan K; Rosen A; Wigley FM
Arthritis Rheumatol; 2015 Apr; 67(4):1053-61. PubMed ID: 25605296
[TBL] [Abstract][Full Text] [Related]
9. Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening.
Lazzaroni MG; Cavazzana I; Colombo E; Dobrota R; Hernandez J; Hesselstrand R; Varju C; Nagy G; Smith V; Caramaschi P; Riccieri V; Hachulla E; Balbir-Gurman A; Chatelus E; Romanowska-Próchnicka K; Araújo AC; Distler O; Allanore Y; Airò P;
J Rheumatol; 2017 May; 44(5):639-647. PubMed ID: 28089973
[TBL] [Abstract][Full Text] [Related]
10. Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma.
Shah AA; Xu G; Rosen A; Hummers LK; Wigley FM; Elledge SJ; Casciola-Rosen L
Arthritis Rheumatol; 2017 Jun; 69(6):1306-1312. PubMed ID: 28217959
[TBL] [Abstract][Full Text] [Related]
11. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.
Shah AA; Rosen A; Hummers L; Wigley F; Casciola-Rosen L
Arthritis Rheum; 2010 Sep; 62(9):2787-95. PubMed ID: 20506513
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.
Igusa T; Hummers LK; Visvanathan K; Richardson C; Wigley FM; Casciola-Rosen L; Rosen A; Shah AA
Ann Rheum Dis; 2018 Aug; 77(8):1179-1186. PubMed ID: 29678941
[TBL] [Abstract][Full Text] [Related]
13. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies.
Harris ML; Rosen A
Curr Opin Rheumatol; 2003 Nov; 15(6):778-84. PubMed ID: 14569210
[TBL] [Abstract][Full Text] [Related]
14. [Systemic scleroderma and malignant diseases. A review of the literature].
Bielefeld P
Rev Med Interne; 1991; 12(5):350-4. PubMed ID: 1771314
[TBL] [Abstract][Full Text] [Related]
15. Childhood-onset scleroderma: is it different from adult-onset disease.
Vancheeswaran R; Black CM; David J; Hasson N; Harper J; Atherton D; Trivedi P; Woo P
Arthritis Rheum; 1996 Jun; 39(6):1041-9. PubMed ID: 8651969
[TBL] [Abstract][Full Text] [Related]
16. Clinical aspects of systemic and localized scleroderma.
Wigley FM
Curr Opin Rheumatol; 1994 Nov; 6(6):628-36. PubMed ID: 7865385
[TBL] [Abstract][Full Text] [Related]
17. Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer.
Betteridge ZE; Priest L; Cooper RG; McHugh NJ; Blackhall F; Lamb JA
Arthritis Res Ther; 2018 Aug; 20(1):176. PubMed ID: 30092841
[TBL] [Abstract][Full Text] [Related]
18. Risk of cancer in patients with scleroderma.
Pearson JE; Silman AJ
Ann Rheum Dis; 2003 Aug; 62(8):697-9. PubMed ID: 12860720
[No Abstract] [Full Text] [Related]
19. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.
Shah AA; Rosen A; Hummers LK; May BJ; Kaushiva A; Roden RBS; Armstrong DK; Wigley FM; Casciola-Rosen L; Visvanathan K
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):71-74. PubMed ID: 28628466
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and pathogenesis of scleroderma.
Chen K; See A; Shumack S
Australas J Dermatol; 2003 Feb; 44(1):1-7; quiz 8-9. PubMed ID: 12581091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
